Gyn Conferences 2022

CME

Expert Analyses of Key Clinical Developments and Updates Across Gynecologic Malignancies

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: January 23, 2023

Expiration: January 22, 2024

Activity

Progress
1
Course Completed

  1. Gadducci A, Cosio S, Landoni F, et al. Response to chemotherapy and clinical outcome of patients with recurrent epithelial ovarian cancer after PARP inhibitor maintenance treatment: a multicenter retrospective Italian study. Anticancer Res. 2022;42:2017-2022.
  2. Gonzalez-Martin A, Pothuri B, Vergote, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381:2391-2402.
  3. Mirza MR, Gonzalez-Martin A, Graybill W, et al. Evaluation of an individualized starting-dose of niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study. Presented at: 2022 American Society of Clinical Oncology Annual Meeting; May 29-31, 2020. Abstract 6050.
  4. Li N, Zhu J, Yin R, et al. Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME study): A randomized, double-blind, placebo controlled, phase 3 trial. Presented at: 2022 Society of Gynecologic Oncology Annual Meeting; March 18-21, 2022. Abstract 244.
  5. O’Malley D, Oza A, Lorusso D, et al. Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma. Gynecol Oncol. 2022;Epub ahead of print.
  6. Vergote I, Peréz Fidalgo A, Hamilton E, et al. Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer. Presented at: 2022 Society of Gynecologic Oncology Annual Meeting; March 18-21, 2022. Abstract 249.
  7. Coleman RL, Lorusso D, Gennigens C, et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicenter, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22:609-619.
  8. Tisotumab vedotin prescribing information. Plainsboro, NJ: Seagen Inc and Genmab US Inc; 2021.
  9. Oaknin A, Pothuri B, Gilbert L, et al. Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability–high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): The GARNET study. Presented at: 2022 American Society of Clinical Oncology Annual Meeting; June 3-7, 2022. Abstract 5509. 
  10. Makker V, Colombo N, Casado Herráez A, et al: A multicenter, open-label, randomized phase 3 study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer: Study 309/KEYNOTE-775. Presented at: 2021 Society of Gynecologic Oncology Annual Meeting; March 19-25, 2021. Abstract 37.
  11. Makker V, Colombo N, Herráez Casado A, et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med. 2022;386:437.
  12. Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for persistent or recurrent cervical cancers. N Engl J Med. 2021;385:1856.
  13. Tewari K, Colombo N, Monk BJ, et al. Pembrolizumab + chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer: subgroup analysis of KEYNOTE-826. Presented at: 2022 American Society of Clinical Oncology Annual Meeting; June 3-7, 2022. Abstract 5506.
  14. Pembrolizumab prescribing information. Whitehouse Station, NJ: Merck & Co., Inc; 2021.
  15. Lorusso D, Vergote I, O’Cearbhaill RE, et al. Tisotumab vedotin (TV) + pembrolizumab (pembro) in first-line (1L) recurrent or metastatic cervical cancer (r/mCC): interim results of ENGOT Cx8/GOG 3024/innovaTV 205. Presented at: 2022 American Society of Clinical Oncology Annual Meeting; June 3-7, 2022. Abstract 5507.
  16. Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly-diagnosed ovarian cancer. N Engl J Med. 2018;379:2495-2505.
  17. DiSilvestro P, Banerjee S, Colombo N, et al. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1/GOG 3004 trial. J Clin Oncol. 2022;Epub ahead of print.
  18. Ray-Coquard I, Leary A, Pignata S, et al. Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC). Presented at: 2022 European Society of Medical Oncology Annual Meeting; September 9-13, 2022. Abstract LBA29.
  19. Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381:2416-2428.
  20. Monk B, Parkinson K, Lim MC, et al. ATHENA–MONO (GOG-3020/ENGOT-ov45): a randomized, double-blind, phase 3 trial evaluating rucaparib monotherapy versus placebo as maintenance treatment following response to first-line platinum-based chemotherapy in ovarian cancer. Presented at: 2022 American Society of Clinical Oncology Annual Meeting; June 3-7, 2022. Abstract LBA5500.
  21. Kristeleit R, Ghamande S, Lim M, et al. Rucaparib maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC): defining benefit according to disease risk subgroups within the phase 3 ATHENA–MONO study. Presented at: 2022 European Society of Medical Oncology Annual Meeting; September 9-13, 2022. Abstract 527MO.
  22. Kristeleit R, Lisyanskaya A, Fedenko A, et al. Rucaparib versus standard-of -care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23:465-478.
  23. Oza AM, Lisyanskaya AS, Fedenko AA, et al. Overall survival results from ARIEL4: A phase III study assessing rucaparib vs chemotherapy in patients with advanced, relapsed ovarian carcinoma and a deleterious BRCA1/2 mutation. Presented at: 2022 European Society of Medical Oncology Annual Meeting; September 9-13, 2022. Abstract 518O.
  24. Rogers L, Shun S, Luesley D, et al. Radiotherapy and chemoradiation after surgery for early cervical cancer. Cochrane Database Syst Rev. 2012;5:CD007583.
  25. Han X, Chang W-W, Xia X. Immune checkpoint inhibitors in advanced and recurrent/metastatic cervical cancer. Front Oncol. 2022;12:996495.
  26. Monk B, Toita T, JC Wu, et al. Durvalumab in combination with and following chemoradiotherapy in locally advanced cervical cancer: results from the phase international, randomized, double-blind, placebo-controlled CALLA trial. Presented at: 2022 International Gynecologic Cancer Society Annual Meeting; September 29 - October 1, 2022. Abstract O001.
  27. Frumovitz M, Chisholm G, Jhingran A, et al. Topotecan, paclitaxel, and bevacizumab in women with recurrent high-grade neuroendocrine carcinoma of the cervix: the NeCTuR study. Presented at: 2022 International Gynecologic Cancer Society Annual Meeting; September 29 - October 1, 2022. Abstract O008.
  28. Leath CA, Scambia G, Villalobos Valencia R, et al. Overall survival by number of prior lines of chemotherapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer receiving olaparib treatment or non-platinum chemotherapy in SOLO3. Presented at: 2022 International Gynecologic Cancer Society Annual Meeting; September 29 - October 1, 2022. Abstract LBA001.
  29. Penson RT, Villalobos Valencia R, Cibula D, et al. Olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1/2 mutation (SOLO3): a randomized phase III trial. J Clin Oncol. 2020;38:1164-1174.
  30. Coleman R, Oza A, Lorusso D, et al. Overall survival results from ARIEL3: a phase 3 randomized double blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. Presented at: 2022 International Gynecologic Cancer Society Annual Meeting; September 29 - October 1, 2022. Abstract O003.
  31. Christinat Y, Ho L, Clément S, et al. The Geneva HRD test: clinical validation on 469 samples from the PAOLA-1 trial. Presented at: 2022 European Society of Gynaecological Oncology Congress; October 27-30, 2022. Abstract RA-567.
  32. Willing EV, Vollbrecht C, Voessing C, et al. Validation study of the NOGGO-GIS assay based on ovarian cancer samples from the first-line PAOLA-1/ENGOT-OV25 phase III trial. Presented at: 2022 European Society of Gynaecological Oncology Congress; October 27-30, 2022. Abstract RA-873.
  33. Loverix L, Vergote I, Busschaert P, et al. Predictive value of the Leuven HRD test compared with Myriad myChoice PLUS on 468 ovarian cancer samples from the PAOLA-1/ENGOT-ov25 trial. Presented at: 2022 European Society of Gynaecological Oncology Congress; October 23-26, 2022. Abstract LBA6.
  34. Coleman RL, Oza A, Lorusso D, et al. Overall survival results from ARIEL3: a phase 3 randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. Presented at: 2022 European Society of Gynaecological Oncology Congress; October 27-30, 2022. Abstract RA-249.
  35. Li J, Chu R, Chen Z, et al. Progress in the management of ovarian granulosa cell tumor: a review. Acta Obstet Gynecol Scand. 2021;100:1771-1778.
  36. Joly F, Ray-Coquard IL, Floquet A, et al. Long-term quality of life after chemotherapy among rare ovarian cancer survivors: the national GINECO case-control VIVROVAIRE rare tumors study. Presented at: 2022 European Society of Gynaecological Oncology Congress; October 27-30, 2022. Abstract RA-605.